Compass Therapeutics (CMPX) stock price is $0.83, down 0.93% on the day, as of Nov 11, 2026. It has a market cap of $151.27Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap151.27 Mn
P/E-1.82
FCF (Yr)-49.17 Mn
ROA (Yr)-36.90
EV to EBIT6.35
Net Income (Yr)-66.49 Mn
Enterprise Value-597.53 Mn
Add ratio to table…
About
Compass Therapeutics Inc is a clinical stage oncology focused biopharmaceutical company developing proprietary antibody based therapeutics to treat multiple human diseases. Its scientific focus centers on the interplay between angiogenesis the immune system and tumor growth to design product candidates that modulate the microvasculature activate effector immune cells and alleviate tumor immunosuppressive mechanisms.
Compass Therapeutics generates revenue primarily through…
Compass Therapeutics Inc is a clinical stage oncology focused biopharmaceutical company developing proprietary antibody based therapeutics to treat multiple human diseases. Its scientific focus centers on the interplay between angiogenesis the immune system and tumor growth to design product candidates that modulate the microvasculature activate effector immune cells and alleviate tumor immunosuppressive mechanisms.
Compass Therapeutics generates revenue primarily through upfront payments milestone payments and royalty receipts from licensing agreements with partners such as ABL Bio and Adimab. The company may also earn revenue from future commercial sales of its product candidates upon receiving regulatory approval.
Compass Therapeutics operates in the highly competitive immuno oncology and angiogenesis therapeutic sectors where it faces large established pharmaceutical companies such as Merck Bristol Myers Squibb Roche AstraZeneca and Pfizer. The company differentiates itself through its proprietary StitchMabs platform which enables the creation of bispecific antibodies that simultaneously engage two distinct biological targets. Early clinical data showing activity in biliary tract cancer colorectal cancer and other solid tumors together with a growing intellectual property portfolio provide additional competitive advantages.
The company serves oncology patients receiving treatment in hospitals clinics and other healthcare settings. Its licensing partners include ABL Bio and Adimab which collaborate on the development and commercialization of specific product candidates.
Sector:HealthcareSector rationaleCompass Therapeutics is a biopharmaceutical company developing antibody-based therapeutics for oncology, which falls directly under the Biotechnology and Pharmaceuticals industries within Healthcare. Its revenue model consists of licensing agreements, milestone payments, and future commercial sales of medical treatments for patients in healthcare settings.Industry:BiotechnologyBiotechnologyPrimaryCompass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, specifically using its proprietary StitchMabs platform to create bispecific antibodies. Its revenue is derived from collaboration and milestone payments from partners like ABL Bio and Adimab, which is characteristic of the Biotechnology industry.Classified using BQ-MICSCIK: 0001738021
Peer percentiles
How Compass Therapeutics ranks
Ranked against the 695 companies in Pharmaceuticals and Biotechnology·58 metrics · as of Nov 11, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last